<DOC>
	<DOCNO>NCT00862277</DOCNO>
	<brief_summary>To evaluate persistence bactericidal antibodies adolescent adult receive one dose Menactra® vaccine approximately four eight year earlier</brief_summary>
	<brief_title>Persistence Bactericidal Antibodies Adolescents Adults Who Had Received Single Dose Menactra® Vaccine</brief_title>
	<detailed_description>Subjects receive one dose Menactra® Menomune® study MTA04 , MTA12 , MTA19 ( NCT00777790 ) , MTA21 ( NCT00777257 ) eligible enrollment trial study . All eligible subject provide blood sample Visit 1 , participation study terminate . An age-matched meningococcal-vaccine naïve control group recruit provide blood sample baseline antibody level evaluation . No vaccine administer study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria : For subject age ≥ 18 year : Informed consent form sign dated subject For subject age &lt; 18 year : Informed consent form sign date subject subject 's parent/legal guardian Subject ( parent/legal guardian subject &lt; 18 year age ) able attend schedule visit comply trial procedure For Group 1 : Previously receive one dose meningococcal vaccine ( Menactra® , receive Study MTA04 , MTA12 , MTA19 , MTA21 ) For Group 2 : Previously receive one dose meningococcal vaccine ( Menomune® , receive Study MTA04 ) For Group 3 : Aged 14 27 year never receive meningococcal vaccine Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede inclusion Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy &gt; 2 week Chronic illness stage could interfere trial conduct completion , opinion investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month might interfere assessment immune response Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C seropositivity History invasive meningococcal disease ( confirm either clinically , serologically , microbiologically ) For Groups 1 2 : Previous vaccination ( include booster ) meningococcal disease , exception Menactra® Menomune® vaccination receive trial MTA04 , MTA12 , MTA19 , MTA21 Subjects deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Received oral inject antibiotic therapy within 72 hour prior blood draw ( temporary criterion )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>27 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
</DOC>